SecBot SecBot

PTCT

PTC THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001070081 Biotech & Drug Discovery
$60.97 −2.52 (−3.97%)
Nov 16 4:00 PM ET · prev $63.49
Market cap
$5.3B
Mid cap
Consensus
Buy
86% Buy or better · 21 analysts
Median target
$98.00
+61% · range $62.00–137.00
1 year
−19.4%
from $75.60 · Nov 17
30 days
−0.9%
from $61.53
52-week range
$59.24–89.55
−32% from high · low Oct 16
Avg volume 20D
1.07M
shares / day
Short interest
7.78M
≈9.3% of shares · −6.3%
Days to cover
7.5
at average volume
Insider net
−$12.6M
0 buyers · 7 sellers · since Jul 6
New fund stakes
2
Q3 2026 13F · 3 exits
Filing reports
27
analyzed by SecBot
SecBot read MIXED 15 reports · 90 days
Balance 1 bearish · 2 bullish · 1 mixed · 11 neutral oldest → newest, height = score
Avg score ·High conf. 9/15

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    7 insiders sold $12.6M.

  • InstitutionsMIXED

    Q3 2026: 36 added (2 new), 29 trimmed or exited. Largest new: Squarepoint Ops $18.3M.

  • AnalystsBULLISH

    18 of 21 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −6.3% to 7.78M shares. 7.5 days to cover, ≈9.3% of shares.

  • TrendRANGE

    5% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
3
exits
$18.3M
in new stakes · top 1 shown
FundMoveSharesValue
WESTFIELD CAPITAL MANAGEMENT CO LPADD2,699,340$174.9M
UBS Group AGDOUBLED1,880,447$121.8M
Pictet Asset Management Holding SATRIM838,077$54.3M
MORGAN STANLEYTRIM761,383$49.3M
Qube Research & Technologies LtdDOUBLED677,037$43.9M
BNP PARIBAS FINANCIAL MARKETSADD569,518$36.9M
BNP Paribas Asset Management Holding S.A.ADD448,489$29.1M
Invesco Ltd.TRIM424,376$27.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 86% rate it Buy or better
Strong Buy7Buy11Hold3Sell0Strong Sell0
12-month targets · 15 analysts

Price is below the lowest target. Median implies +61%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 2, 2026Citigroup
MAINTAIN
MAINTAINBuy
Oct 30, 2026TD Cowen
MAINTAIN
MAINTAINBuy
Oct 30, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 30, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight
Oct 8, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Sep 22, 2026Cantor Fitzgerald
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$12.6M
sold · 7 insiders
DateInsiderTypeValue
Oct 14, 2026
SCHMERTZLER MICHAEL
Director
Oct 14, 2026
SELL$126.1K
Oct 14, 2026
SCHMERTZLER MICHAEL
Director
Oct 14, 2026
SELL$23.0K
Oct 9, 2026
Boulding Mark Elliott
EXEC. VP AND CLO
Oct 9, 2026
EXERCISE$7.6K
Oct 9, 2026
Boulding Mark Elliott
EXEC. VP AND CLO
Oct 9, 2026
SELL$12.3K
Oct 7, 2026
SCHMERTZLER MICHAEL
Director
Oct 7, 2026
SELL$3.4K
Oct 7, 2026
SCHMERTZLER MICHAEL
Director
Oct 7, 2026
SELL$155.1K
Oct 6, 2026
Boulding Mark Elliott
EXEC. VP AND CLO
Oct 6, 2026
EXERCISE$17.1K
Oct 6, 2026
Boulding Mark Elliott
EXEC. VP AND CLO
Oct 6, 2026
SELL$27.9K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.52-$0.01–$1.38+279.6%$313.4M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

46 lobbying filings and 8 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
7,779,250
shares short
-6.3%
vs prior settlement
7.5
days to cover
≈9.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 3, 2026 Press
PTC Therapeutics announced a $500 million share repurchase program, representing ~9.3% of its $5.4B market cap. The…
Impact 3/10
Nov 3, 2026 Buyback
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced th
Oct 14, 2026 Insider
SCHMERTZLER MICHAEL sold 2,118 shares
Director @ $59.52 ($126.1K)
Oct 14, 2026 Insider
SCHMERTZLER MICHAEL sold 382 shares
Director @ $60.14 ($23.0K)
Oct 9, 2026 Insider
Boulding Mark Elliott acquired via exercise 192 shares
EXEC. VP AND CLO @ $39.42 ($7.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
9 drugs tracked · Drug pipeline →
Recent
Nov 3, 2026
Buyback
PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share…
Nov 2, 2026
Press release
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following…
Oct 30, 2026
Press release
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved…
Oct 29, 2026
Earnings result
PTCT Q3 2026 Earnings: EPS $0.61 (+75.6% vs est)
Oct 22, 2026
Earnings date
PTCT Q3 2026 Earnings After Market Close, 2026-10-22

SecBot reports

27 filings · 2 press releases · 2 bullish · 3 bearish · 1 mixed · 21 neutral
All PTCT filing & press-release reports (29)